Photo from Jan-Henning Klusmann/LinkedIn
Jun 19, 2023, 18:50
87.7% complete response in 28 days
In a post by Jan-Henning Klusmann on LinkedIn, it says, “Great news from our Department of Pediatrics at Goethe-Universität Frankfurt and Universitätsklinikum Frankfurt am Main:
CD19 CAR T-cells 🛡 (Tisa-cel) show promise for relapsed B-lineage leukemia post-transplant 🧬:
✅87.7% complete response in 28 days
✅2-yr event-free survival 45.3%
🔑Better outcomes if relapse >6 months post-transplant.”
Source: Jan-Henning Klusmann/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 21, 2025, 20:46
Apr 21, 2025, 20:30
Apr 21, 2025, 20:11
Apr 21, 2025, 19:55
Apr 21, 2025, 19:12
Apr 21, 2025, 18:19
Apr 21, 2025, 18:00
Apr 21, 2025, 17:40
Apr 21, 2025, 17:35